Sacral insufficiency fractures after high-dose carbon-ion based radiotherapy of sacral chordomas by Bostel, Tilman et al.
RESEARCH Open Access
Sacral insufficiency fractures after high-
dose carbon-ion based radiotherapy of
sacral chordomas
Tilman Bostel1,2,3*, Nils Henrik Nicolay1,2,3, Thomas Welzel1,3, Thomas Bruckner4, Matthias Mattke1,3, Sati Akbaba1,3,
Tanja Sprave1,3, Jürgen Debus1,2,3 and Matthias Uhl1,3
Abstract
Background: This study aimed to analyse the frequency and clinical relevance of sacral insufficiency fractures (SIFs)
after high-dose carbon-ion based irradiation of sacral chordomas.
Methods: A total of 56 patients were included in this retrospective study. Twenty one patients (37%) were treated
with definitive radiotherapy (RT), and 35 patients (63%) received postoperative RT using carbon ions, either in
combination with photons or as single-modality treatment (median radiation dose 66 Gy RBE, range 60–74 Gy).
Follow-up examinations including MRI of the pelvis were performed at 3-monthly intervals in the first year and
consecutively at 6-monthly intervals. Median follow-up was 35.5 months (range 2–83).
Results: SIFs were diagnosed in 29 patients (52%) after a median follow-up of 11 months (range 1–62 months).
Most sacral fractures (79%) occurred within 2 years after RT. For the overall study population, the fracture-free
survival probability amounted to values of 0.68 (95% CI, 0.53–0.79) after 1 year, 0.46 (95% CI, 0.31–0.60) after 2 years,
and 0.31 (95% CI, 0.16–0.47) after 5 years. Statistical analysis showed no significant difference regarding the fracture
rates between patients who received an operation and postoperative RT and patients treated with definitive RT.
About one third of the patients with SIFs (34%; 10 of 29 patients) had associated clinical symptoms, most notably
pain. All patients with symptomatic fractures required strong analgesics and often intensive pain management.
Conclusions: Sacral fractures after high-dose carbon ion-based RT of sacral chordomas were shown to be a
considerable radiogenic late effect, affecting about half of the treated patients. However, only one third of these
fractures were clinically symptomatic requiring regular medical care and pain therapy.
Further hazard factor analysis in the future with larger patient numbers will possibly enable the identification of
high-risk patients for developing SIFs with the ultimate goal to prevent symptomatic fractures.
Background
Chordoma is a rare, slow-growing, malignant bone tumor
that arises from embryonic remnants of notochord rest
cells [1]. These tumors typically manifest in the midline of
the neuroaxis with the sacrum being the most common
localization. Surgical en-bloc resection is still regarded as
the standard of care for sacral chordomas improving local
control and disease-free-survival [2].
However, sacral chordomas often reach an enormous
size at the time of diagnosis, and the primary surgical
treatment bears the risk of substantial postoperative
morbidity such as bladder and rectal paralysis, chronic
neuropathic pain and/or sensomotoric deficits due to
close proximity of the tumor to neurologic structures,
which are often infiltrated or encased at the time of
diagnosis [3, 4]. Thus, resection margins are very often
marginal or positive [2, 5] which is the reason why adju-
vant radiotherapy (RT) is commonly used to reduce the
risk of local recurrence [6].
Furthermore, definitive high-dose RT is an alternative
effective treatment option for patients who are consid-
ered inoperable or who refuse surgical treatment. In the
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last decade, particle therapy (protons/carbon ions) has
been established as a preferred radiation technique for sa-
cral chordomas. Several studies reported high local tumor
control rates of up to 94% after 5 years when surgery was
combined with adjuvant RT [7]. High-dose RT alone has
also shown very promising local control rates of up to
88% after 5 years and, in addition, a better preservation of
the urinary-anorectal function than surgery [8–11].
However, RT can also cause significant toxicity such as
chronic pain syndromes, aggravation of pre-existent
motor and sensory functions or even new nerve injuries.
In this context, sacral insufficiency fractures (SIFs) may
be an important causative factor for increasing morbidity
of patients. Several studies already adressed the inci-
dence of SIFs after RT from visceral tumors in the pelvis
and found only a low fracture rate ranging from 3 to
11% [12–17]. For sacral chordoma, only one recently
published study from the Massachusetts General Hos-
pital (MGH) in Boston addressed concerns regarding
SIFs after high-dose radiation treatment; Osler et al. re-
ported a relatively high rate of SIFs following high-dose
proton-based RT (47%), in particular when surgery was
combined with perioperative radiation treatment [18].
The purpose of our study was to determine the inci-
dence of SIFs after definitive high-dose radiation treat-
ment of sacral chordoma using carbon ion therapy alone
or in combination with photons. Furthermore, the time
until fracture, the clinical relevance and prognostic fac-
tors for development of SIFs were assessed.
Patients and methods
Patients
Fifty-six patients with histologically confirmed sacral
chordomas were included in this retrospective study. All
study patients received high-dose RT at our department
in the time period between November 2009 and Decem-
ber 2012. The characteristics of all study patients are
summarized in Table 1. The independent ethics commit-
tee of the Heidelberg University Medical Faculty ap-
proved this retrospective analysis.
Treatment
Patients were treated either by carbon ion therapy alone
or by a combination of photons and carbon ions based
on a CT scan and an additonal MRI scan. Primary RT
was applied to 21 patients (37%), whereas the majority
of the study population (n = 35; 63%) received RT in the
postoperative situation (see Table 2). For contouring of
the treatment volumes and organs at risk we used the
Siemens Oncologist software tools (Siemens, Erlangen,
Germany). Macroscopic tumor volume based on MRI
was defined as the gross tumor volume (GTV). In most
patients (n = 49; 88%), we applied a boost plan, in which
the clinical target volume (CTV1) covered the GTV and/
or the tumor bed plus an additional safety margin of 3–
5 mm. For the primary plan, the clinical target volume
(CTV2) encompassed not only the CTV1 with safety mar-
gins but also the typical ways of tumor spread, i.e. the
whole sacrum was commonly included. Furthermore, a
small safety margin of 3–7 mm was added to the clinical
target volumes (CTV1 and CTV2) to generate the plan-
ning target volumes (PTV1 and PTV2). In the subgroup
of patients treated with carbon ions alone, the total ap-
plied dose was 60–66 Gy RBE applied in 20–22 fractions
with a single dose of 3 Gy RBE (see Table 2). In the sub-
group of patients who received a bimodal radiation, the
treatment concept consisted of an irradiation with 50 Gy
photons in 25 fractions (single dose 2 Gy) and 15–24 Gy
RBE carbon ions in 5–8 fractions (single dose 3 Gy RBE).
Follow up and assessment of sacral insufficiency fractures
In the first year after completion of treatment, follow-up
examinations including MRI of the pelvis were con-
ducted 6–8 weeks after RT and then at 3-monthly inter-
vals, and in the following years at 6-monthly intervals.
Table 1 Patients’ characteristics
Characteristics Value Percent
Age (y)
Median 61
Range 34–84
Gender (n)
Female 19 33.9
Male 37 66.1
Most cranial level of the tumor (n)
L4/5 7 12.5
S1 9 16.1
S2 18 32.1
S3 12 21.4
S4 4 7.1
S5 4 7.1
Os coccygeum 2 3.6
Sacral BMD in planning CT (HU)
Median - 18.5
Range - 89 – 151
SIFs (n) 29 51.8
Time to SIF (months)
Median 11.5
Range 0–62
Clinical relevance of SIFs (n)
Pain 10 34.5
Neurologic deficits 1 3.4
Abbreviations: BMD Bone marrow density; SIFs Sacral insufficiency fractures;
HU Hounsfield Units; CT Computed tomography; n Number; y Years
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The median follow-up was 35.5 months (range 2–
83 months). The MR images were reviewed by a
board-certified radiologist for presence of SIFs in a blinded
manner, i.e. the radiologist did not have informations about
the current health status or clinical problems of the study
patients. The MR diagnosis of SIFs was based on detection
of a fracture line with strongly decreased signal on T1- and
T2-weighted images and surrounding medullary edema
with decreased signal on T1-weighted images and increased
signal on T2-weighted images. If MR imaging patterns indi-
cative for a SIF were found, an additional CT scan of the
pelvis was commonly performed to confirm the diagnosis.
Medical records were reviewed for correlation of insuffi-
ciency fractures with associated clinical symptoms.
Statistics
Statistical analysis was done using the SAS software ver-
sion 9.3 (SAS Institute, Cary, NC, USA). A p-value of p
< .05 was considered statistically significant (Chi square,
two-sided Wilcoxon test and Log-rank test). Fracture-free
survival was plotted according to the Kaplan-Meier
method. The log-rank test was used for comparison of the
fracture-free survival times between different treatment
groups.
Age, tumor volume, sex, radiation dose, bone marrow
density, status post operation and status post high sacrect-
omy were tested for their prognostic significance for pre-
dicting SIFs using the Wilcoxon or Chi square test.
Results
In 52% of the patients (29 of 56 patients), we found SIFs
in the follow-up examinations (see Fig. 1). The median
time until fracture was 11 months (range 1–62 months).
The majority of the affected patients developed the frac-
tures within 2 years after RT (79%; 23 of 29 patients).
For the overall study population, fracture-free survival
probability amounted to values of 0.68 (95% CI, 0.53–
0.79) after 1 year, 0.46 (95% CI, 0.31–0.60) after 2 years,
and 0.31 (95% CI, 0.16–0.47) after 5 years (see Fig. 2).
No statistically significant difference was evident con-
cerning the sacral fracture rates between patients who
received a combination therapy of surgery and radiation
(57%; 20 of 35) and patients treated with RT alone (43%;
9 of 21) (p = 0.23) (see Fig. 3).
In the subgroup of patients treated with sacrectomies
and additional RT, the 1-, 2- and 5-year probabilities for
freedom of sacral fractures were 0.68 (95% CI, 0.48–
0.81), 0.43 (95% CI, 0.24–0.61) and 0.16 (95% CI, 0.03–
0.38). In the subgroup of patients treated with definitive
RT, the 1-, 2- and 5-year fracture-free survival probabil-
ities amounted to values of 0.63 (95% CI, 0.37–0.80),
0.50 (95% CI, 0.26–0.71) and 0.50 (95% CI, 0.26–0.71),
respectively.
We also found no statistically significant difference
when comparing the high sacrectomy group (i.e., S1-S3
level) with the low sacrectomy group (i.e., below S3
level) and radiation-only group (p = 0.49) (see Fig. 4).
Table 2 Treatment
Characteristics Value Percent
Resection status (n)
Biopsy 24 42.9
R2 19 33.9
R0/1 13 23.2
Treatment (n)
Primary 42 75.0
S.p. biopsy 21 50.0
S.p. R0/1 resection 10 23.8
S.p. R2 resection 11 26.2
Recurrent 14 25.0
Additional biopsy 1 7.1
Additional R0/1 resection 4 28.6
Additional R2 resection 9 64.3
Radiation dose ED 2 Gy
Carbon ion only: (α/β = 2)
60 Gy/3 Gy (RBE) 75.0 Gy 16 28.6
63 Gy/3 Gy (RBE) 78.8 Gy 2 3.6
66 Gy/3 Gy (RBE) 82.5 Gy 15 26.8
IMRT + carbon ion boost
50 Gy/2 Gy + 15 Gy/3 Gy (RBE) 68.8 Gy 1 1.8
50 Gy/2 Gy + 18 Gy/3 Gy (RBE) 74.5 Gy 1 1.8
50 Gy/2 Gy + 24 Gy/3 Gy (RBE) 80.0 Gy 21 37.5
GTV (n = 43; ml)
Median 244
Range 5–1188
CTV1 (n = 43; ml)
Median 522
Range 64–1743
CTV2 (n = 56; ml)
Median 937.5
Range 60–2404
PTV1 (n = 43; ml)
Median 614
Range 0–2325
PTV2 (n = 56; ml)
Median 1067
Range 84–3099
Abbreviations: GTV Gross tumor volume; CTV1 Clinical target volume 1 (boost
plan); CTV2 Clinical target volume 2 (primary plan); PTV1 Planning target
volume 1 (boost plan); PTV2 Planning target volume 2 (primary plan); RBE
Relative biological effectiveness; IMRT Intensity modulated radiotherapy; n
Number; ml Milliliter; s.p. Status post
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In addition, patients’ age and gender, the volume of
the tumors, the bone marrow densities prior to RT, the
radiation dose and the extent of surgical resection (i.e.,
high sacrectomy vs. low sacrectomy) were analysed re-
garding the fracture rates. None of these factors was
shown to be statistically significant for prediction of SIFs
(see Table 3).
About one third of the patients with SIFs (34%; 10 of
29 patients) had associated clinical symptoms, of which
pain was the main physical impairment (see Table 1). All
patients with symptomatic fractures required strong an-
algesics and often intensive care by a pain therapist; in 1
patient with a SIF, screw fixation of the sacrum was
performed.
Discussion
To date, most toxicity analyses after high-dose radiation
of sacral chordoma mostly focused on clinical symptoms
(e.g., chronic pain or skin problems) or neurologic im-
pairment (e.g. bladder and rectal paralysis, sensomotoric
deficits) [19], but the incidence of SIFs was rarely dir-
ectly addressed and has therefore probably been under-
estimated in past studies [2, 5]. Thus, Osler et al.
systematically assessed SIFs after high-dose RT of sacral
chordoma in a retrospective study and reported about
relative high fracture rates in nearly half of the study
population, and the proportion was even higher in pa-
tients who received a high sacrectomy prior to radiation
[18]. In this study, RT was proton-based and carried out
in combination with surgical resection or alone in situa-
tions where sacral chordomas were not resectable or pa-
tients refused their consent for surgery.
In summary, the available study data on SIFs after RT
of sacral chordoma are very limited and no data exist
concerning the incidence of fractures after carbon ion
RT. We therefore aimed to specifically evaluate the rates
of SIFs after high-dose carbon- ion-based RT and to
compare it with recently published data from the MGH
Boston.
In line with the results of Osler et al. [18], we found a
relatively high fracture rate of 52% after a median
follow-up of about 3 years. The majority of the fractures
developed in a time frame of 2 years. However, in 22%
of the affected patients fractures were diagnosed later
than 2 years after radiation. The slightly higher fracture
rate in our study compared to the analysis of the MGH
Boston is therefore most likely explainable by the longer
median follow-up time in our study (35.5 months vs.
22 months) [18].
An important finding in our study was that about two
thirds of SIFs were clinically asymptomatic. Among the
symptomatic fractures, new or increased low back pain
was by far the leading impairment of affected patients,
a
d e
b
c
f
g
Fig. 1 47-year-old man with an extended sacral chordoma (black
star) as shown on axial T1- and T2-weighted MR-images before
definitive radiotherapy (a, b, c), and on the planning CT with the
corresponding dose distribution (d and e). The post-treatment MRI
12 months after radiation shows sacral insufficiency fractures in both
massae laterales of the sacrum (white arrows) with corresponding
hypointense linear signal abnormalities on both T1- and T2-
weighted MR-images (f and g). The T2-weighted axial images (g)
additionally depict the surrounding hyperintense bone marrow
edema (yellow stars) which mimics tumor progression
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resulting in mobility restrictions and requiring pain
medication.
In contrast to the study data from Osler et al. [18], we
did not observe a statistically significant difference of frac-
ture rates between patients treated with a combination of
surgery and high-dose radiation compared to high-dose
radiation alone. In addition, we analysed patients’ age and
gender, the volume of the tumors, the bone marrow dens-
ity prior to RT, the radiation dose and the extent of surgi-
cal resection (i.e., high sacrectomy vs. low sacrectomy)
and found none of these factors to be statistically relevant
for prediction of SIFs.
Our study has several limitations, among them the
retrospective character of the dataset. Secondly, 9 of the
56 study patients were lost to follow-up by 1 year (16%);
thus, the fracture rate may even be higher than reported
in our study. Moreover, we cannot rule out a small bias, as
the 1-year lost to follow-up rate was 19% in the operation
group (6 of 32 patients) and 13% in the radiation only
group (3 of 24 patients). As a consequence, SIFs might
have been more often underdiagnosed in the surgery
group than in the radiation-only group, which would have
affected our comparison analysis among treatment groups.
Another important limitation is the limited number of
Fig. 2 Fracture-free survival probability for the entire patient cohort
Fig. 3 Comparison of the fracture-free survival probabilities between the non-surgical group (solid line) and surgical group (dashed line)
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study patients, particularly with regard to the risk factor
analysis.
Additionally, we were not able to statistically analyze the
exact further therapies of SIFs, their response to treat-
ment, of the resulting restrictions in patients’ daily living
activities and fracture healing in the further course; this
study does therefore not provide a reliable response to the
question which therapeutic measures need to be taken in
the case of symptomatic SIFs for an optimal patient care.
Nevertheless, the result of radical resection in patients
with sacral chordoma in S2 and higher (60% of patient in
our study) would have been a complete urinary and bowel
incontinence in at least 80% of the patients [3, 20]. Fur-
thermore chronic neuropathic pain, wound complications
and walking difficulties are common side effects of
sacrectomy [4, 21]. Therefore, the rate of 18% patients
with symptomatic SIFs after irradiation should be assessed
against this background.
Conclusion
About half of patients undergoing high-dose carbon-ion
based radiation of sacral chordomas developed sacral
fractures during the further course of their disease,
mostly within two years after radiation. However, only
one third of those fractures resulted in clinical symp-
toms such as pain or neurologic deficits.
The results of this study emphasize the importance of
a regular and close follow-up of patients, whereby radi-
ologists have a pivotal role in the patient care, as the
correct interpretation of the imaging scans is a pre-
requisite for initiation of appropriate therapeutic mea-
sures. Further hazard factor analysis in the future will
possibly enable the identification of high-risk patients
for developing SIFs with the ultimate goal to prevent
those patients from symptomatic fractures.
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